European drugmaker Novartis (NVS), best known for blockbuster drugs like Entresto, Cosentyx, and Kesimpta, just announced a ...

Trump's recent announcement that he's procured $7 trillion in incoming investments to the U.S. may very well have been an underestimate.

The pharmaceutical firm will establish a research innovation hub in California, and manufacturing facilities in Florida, ...

Vas Narasimhan is global head of drug development and chief medical officer at Novartis, and spoke to pharmaphorum at the company’s recent Q4 results conference. He says numerous pilot studies ...

Swiss pharmaceutical giant Novartis announced it will spend $23 billion to build and expand 10 facilities in the United ...

Swiss pharmaceutical giant Novartis announced Thursday that it plans to build a $1.1 billion research hub in San Diego as ...

Novartis (NVS, Financials) is investing $23 billion over the next five years to expand its manufacturing and research ...

Novartis appoints Karen Hale as chief legal and compliance officer: Basel Tuesday, April 1, 2025, 13:00 Hrs [IST] Novartis announced the appointment of Karen Hale to the expanded ...

Novartis plans to spend $23 billion over the next five years to expand its manufacturing, research and technology presence in the U.S.

It makes a wide range of treatments from cancer to cardiovascular drugs. Vas Narasimhan, chief executive of Novartis, said the investments reflected the “pro-innovation policy and regulatory ...

Novartis chief executive Vas Narasimhan, already eyeing a possible divestment of generics business Sandoz, has now turned his attention to the rest of the company. The Swiss group will see major ...